Article
Bumetanide for autism: more eye contact, less amygdala activation
20 Feb 2018
Abstract excerpt
We recently showed that constraining eye contact leads to exaggerated increase of amygdala activation in autism. Here, in a proof of concept pilot study, we demonstrate that administration of bumetanide (a NKCC1 chloride importer antagonist that restores GABAergic inhibition) normalizes the level of amygdala activation during constrained eye contact with dynamic emotional face stimuli in autism. In addition,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
